Fundamentals → charts → levels → plan | value, growth & speculative stocks | clear entries, targets, catalysts & invalidations | NFA | Join our Patreon below 👇
Joined October 2024
- Tweets11K
- Following532
- Followers36.8K
- Likes22.8K
Pinned Tweet
Here's what's inside the Chasers group:
1,000+ members
- My personal buy and sell alerts, shared in real time
- Weekly Recaps: deep technical + fundamental analysis on 8 stocks every Sunday
- Daily chart updates
- Gamma exposure updates
- News on our top 15 stocks
- Earnings breakdowns
- Deep fundamental analysis
- Educational content, from zero to advanced
- An active community of like-minded investors
We don't just give you stocks
We teach you how to find them yourself
For less than $1 a day
patreon.com/c/StockChaser_
$FCEL is a stock I currently have on my watchlist
It has done a nice ABC corrective move so far, exactly what we normally want to see after the rejection of Wave 5
Right now we’re in a very important confluence zone where the bulls should step in and defend these levels: a key support zone and the 0.786 fib level at the same time
A hold here, and a new impulse wave could be coming next
For confirmation of the start of a new impulse wave, I’d like to see the 200 MA reclaimed
NFA
$IREN is down 48% YTD, but institutional ownership keeps growing
$ONDS is down 48% YTD, but institutional ownership keeps growing
$TE is down 67% YTD, but institutional ownership keeps growing
$SOFI is down 40% YTD, but institutional ownership keeps growing
This disconnect won’t last forever
Price will eventually catch up, and everyone will realize that the prices we’re seeing right now were real opportunities
NFA
This week we record the first of the 2 CEO interviews we have lined up this month
Things are starting to get more and more interesting
We’re leveling up the value we bring to you guys
Thank you to every single one of you who has been part of this family
$SOFI is back in the consolidation range
The next step is a breakout and a flip of the 0.5 fib level into support
Long term price target: $61
Remember this
NFA
“And those who were seen dancing were thought to be insane by those who could not hear the music.”
This applies to everything in life
Conviction, determination, effort
Keep dancing
Don’t say we didn’t warn you about this move when $ASTS was above $100
It couldn’t hold above the 0.618 fib level
Now we’re looking at the 0.786 fib level for support to hold next
NFA
I have a nice pile of cash ready to be deployed soon
Every buy gets shared inside the group
Link to join is in bio
Beautiful analysis on $ASML
Once again
NFA
$ASML reached our Wave 3 target, a +150% move since we shared the chart
It has since pulled back, which is exactly what we expected
Wave 4 corrective move in play, this is healthy structure
The levels I'm watching for the correction:
The 0.382 and 0.5 fib levels
NFA
$TE signed last week new offtake deals for more than 1.58GW of solar modules
This includes agreements with subsidiaries of Avantus
$TE expects to supply the TOPCon modules from G1_Dallas in 2027-2028 using a mix of imported cells and cells from G2_Austin
$TE says more than 4GW of its 2027 module manufacturing capacity is now under contract
This gives much better demand visibility for G1_Dallas and supports the domestic content increase as G2_Austin comes online
While the financing package has not yet been released, the first 2.1GW phase of G2 is expected to start producing cells in Q1 2027
Our focus for $TE is still clear: securing the remaining G2_Austin financing and delivering the cell fab on schedule
What are your thoughts on $TE here?
$VOYG beat revenue expectations but profitability is still under pressure
Q3 results:
✅ Revenue: $88.7M vs. $81.4M expected, up 124% YoY and 68% QoQ
❌ Gross margin: 11.5%, down from 15.4% a year ago
❌ Adjusted EBITDA: −$44.9M, compared with −$37.5M in Q2
Guidance:
• FY2026 revenue outlook raised to $285–305M from $275–305M
What stood out:
• Backlog reached a record $742M, up 121% from Q2, including $347M added through Astrobotic
• Bookings hit a record $116M, a 1.3x book-to-bill ratio
• Signed Starlab commercial reservations rose to $700M from $500M
The demand side of the $VOYG thesis is strengthening: revenue, bookings and backlog are all moving higher
But the near-term focus is for revenue growth to translate into better profitability
What where your thoughts on the quarter?
$PLTR reports earnings today after the close
And look at the chart: it has bounced 100% from the 0.5 fib level, exactly where we expected it to
Let’s see what these earnings bring us
NFA
$PLTR price action created a lot of perma-bulls
Unfortunately, we may finally get the ABC retracement it needs
Valuation:
• P/S 137× → 105×
• P/E 484× → 416×
Even after the pullback, the valuation is still outrageous no matter how good the tech is (TTM growth is only at 47%)
At such extended valuations, a >50% drawdown from ATH would not be shocking
Still long-term bullish but the fundamentals need to catch up
StockChaser retweeted
$HIMS has not moved much over the past 3 months
Price has been staying at support
Meanwhile, the peptide opportunity is moving forward
On Wednesday, HHS released a draft interim policy covering six peptides, including BPC-157 and TB-500.
While formal rulemaking proceeds, HHS says it does not intend to take enforcement action against qualifying pharmacies and physicians compounding these peptides
Why it matters for $HIMS:
• It acquired a California peptide manufacturing facility in February 2025, positioning it to produce ingredients in-house
• On October 29, it previewed Peptides+, with planned access to sermorelin, glutathione, NAD+, B12 and L-carnitine
• BPC-157 and TB-500 would follow “when allowable.” There is no confirmed launch date for those treatments
The market?
• Leerink estimated a $2.2B telehealth market for seven wellness peptides in 2027
• Needham put the opportunity at up to $3.3B if restrictions eased
A broader estimate from Needham puts the addressable peptide market near $30B
For $HIMS, the importance is about revenue AND manufacturing economic
At a 2.5x PS, you are not even paying for future optionalities
What are your thoughts?
$HIMS has not moved much over the past 3 months
Price has been staying at support
Meanwhile, the peptide opportunity is moving forward
On Wednesday, HHS released a draft interim policy covering six peptides, including BPC-157 and TB-500.
While formal rulemaking proceeds, HHS says it does not intend to take enforcement action against qualifying pharmacies and physicians compounding these peptides
Why it matters for $HIMS:
• It acquired a California peptide manufacturing facility in February 2025, positioning it to produce ingredients in-house
• On October 29, it previewed Peptides+, with planned access to sermorelin, glutathione, NAD+, B12 and L-carnitine
• BPC-157 and TB-500 would follow “when allowable.” There is no confirmed launch date for those treatments
The market?
• Leerink estimated a $2.2B telehealth market for seven wellness peptides in 2027
• Needham put the opportunity at up to $3.3B if restrictions eased
A broader estimate from Needham puts the addressable peptide market near $30B
For $HIMS, the importance is about revenue AND manufacturing economic
At a 2.5x PS, you are not even paying for future optionalities
What are your thoughts?